» Articles » PMID: 32013992

Anal Function and Quality of Life Analysis After Laparoscopic Modified Parks for Ultra-low Rectal Cancer Patients

Overview
Publisher Biomed Central
Date 2020 Feb 5
PMID 32013992
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: To assess postoperative anal function and quality of life of ultra-low rectal cancer patients treated by laparoscopic modified Parks surgery.

Methods: From February 2017 to March 2019, 114 patients with ultra-low rectal cancer above T2 were treated respectively with ultra-low anterior resection (Dixon), modified coloanal anastomosis (modified Parks), and Miles according to the preoperative stage and anastomotic position. The postoperative anal function and Fecal Incontinence Quality of Life Scale (FIQL) of each patient were collected and synthetically analyzed.

Results: Compared with the Dixon group, the postoperative anal function and FIQL in the Parks group were poor at the early stage. However, from 6 to 12 months after surgery, the scores of anal function and FIQL in the Parks group were similar to those in the Dixon group (P > 0.05). Compared with the Miles group, the FIQL of the two groups were similar in the early postoperative stage. However, with the passage of time, from 3 to 9 months after surgery, the four domains of FIQL in the Parks group were higher than those in the Miles group successively (P < 0.05).

Conclusions: Laparoscopic modified Parks is a safe, effective, and economical anus-preserving surgery. Although its early anal function and FIQL were poor, it could gradually recover to the similar level as Dixon. Moreover, it can save the anus and obtain a better postoperative quality of life for some patients who previously could only undergo Miles.

Citing Articles

Evaluation of the learning curve for conformal sphincter preservation operation in the treatment of ultralow rectal cancer.

Ding H, Wang L, Sun G, Yu G, Gao X, Zheng K World J Surg Oncol. 2022; 20(1):102.

PMID: 35354489 PMC: 8966240. DOI: 10.1186/s12957-022-02541-1.


Quality of life in restorative versus non-restorative resections for rectal cancer: systematic review.

Lawday S, Flamey N, Fowler G, Leaning M, Dyar N, Daniels I BJS Open. 2022; 5(6).

PMID: 35040944 PMC: 8765336. DOI: 10.1093/bjsopen/zrab101.


The efficacy of ileostomy after laparoscopic rectal cancer surgery: a meta-analysis.

Mu Y, Zhao L, He H, Zhao H, Li J World J Surg Oncol. 2021; 19(1):318.

PMID: 34732226 PMC: 8567543. DOI: 10.1186/s12957-021-02432-x.

References
1.
Bossema E, Seuntiens M, Marijnen C, Baas-Thijssen M, van de Velde C, Stiggelbout A . The relation between illness cognitions and quality of life in people with and without a stoma following rectal cancer treatment. Psychooncology. 2010; 20(4):428-34. DOI: 10.1002/pon.1758. View

2.
Mascagni D, Pironi D, Pontone S, Tonda M, Eberspacher C, Panarese A . Total fistulectomy, sphincteroplasty and closure of the residual cavity for trans-sphincteric perianal fistula in the elderly patient. Aging Clin Exp Res. 2016; 29(Suppl 1):101-108. DOI: 10.1007/s40520-016-0652-0. View

3.
Yamada K, Saiki Y, Takano S, Iwamoto K, Tanaka M, Fukunaga M . Long-term results of intersphincteric resection for low rectal cancer in Japan. Surg Today. 2019; 49(4):275-285. DOI: 10.1007/s00595-018-1754-4. View

4.
Fokas E, Allgauer M, Polat B, Klautke G, Grabenbauer G, Fietkau R . Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12. J Clin Oncol. 2019; 37(34):3212-3222. DOI: 10.1200/JCO.19.00308. View

5.
Dossa F, Acuna S, Rickles A, Berho M, Wexner S, Quereshy F . Association Between Adjuvant Chemotherapy and Overall Survival in Patients With Rectal Cancer and Pathological Complete Response After Neoadjuvant Chemotherapy and Resection. JAMA Oncol. 2018; 4(7):930-937. PMC: 6145724. DOI: 10.1001/jamaoncol.2017.5597. View